Fig. 10: Mechanistic action of rCD5L.
From: CD5L as a promising biological therapeutic for treating sepsis
Intravenous administration of rCD5L leads to elevated levels of free bioactive protein in the peritoneal cavity (1). Upon binding to target cells of non-hematopoietic origin (2), rCD5L induces significant production of the CXCL1 chemokine (3). The production of CXCL1 establishes a chemotactic gradient, resulting in heightened neutrophil activation (4) and recruitment from the bloodstream (5). The exact mechanism behind neutrophil activation, whether through increased CXCL1 levels or direct action of rCD5L, remains unclear. Increased neutrophil presence in the peritoneal cavity, coupled with the synergistic effect of rCD5L in bacterial binding and enhanced phagocytosis, facilitates efficient bacterial clearance (6). rCD5L aids in the effective removal of DAMPs, likely from both the bloodstream and the peritoneum (7). Endogenous local release of CD5L from resident macrophages contributes to the overall pool of free CD5L at the site of infection. This illustration is for explanatory purposes and is not drawn to scale. Created with Biorender.com.
